Dmitry Balyasny’s 10x Genomics TXG Stock Holding History

Dmitry Balyasny’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65,000	Closed	-$3.63M	–	2809
2023 Q1	$3.63M	Buy	+65,000	New	+$3.04M	0.01%	1205

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dmitry Balyasny's TXG Position: Q2 2026 in Review

Dmitry Balyasny sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 989,522 shares — an estimated $21M sold.

Dmitry Balyasny first reported a position in TXG in Q2 2020 and held it in 10 quarters. The position peaked at $37.8M in Q1 2023. 389 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Dmitry Balyasny reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 989,522 10x Genomics shares in Q2 2026, an estimated $21M.
Dmitry Balyasny first reported a position in 10x Genomics in Q2 2020 and held it in 10 quarters.
Dmitry Balyasny's 10x Genomics position peaked at $37.8M in Q1 2023.
389 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.